NASDAQFinancialsInsurance - SpecialtySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ITIC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS near $14.59 in FY 2025 | A primary condition in Investors Title Co.'s published investment case. The stated target is >= $14.59 per share. | Broken | EPS falls below $14.59 in FY 2025 | Diluted EPS: $7.73 per share FY2026-Q2; GAAP. Published target: >= $14.59 per share. Target period ends 2025-12-31; this observation covers 2026-Q2. Aug 10, 20267.73 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
ITIC is a financial-sector business with a growth-and-execution thesis, rather than a turnaround or a speculative growth story. The multi-year view is intact, and recent signals have shifted from mixed to mildly favorable.
Valuation is cheap versus peers, and the evidence describes expectations as broadly aligned with the business outlook. The priced-in fragility assessment is low, though the expectations gap is negative, so confidence in that valuation read is not complete.
Near-term results have improved: revenue grew year over year in the first two quarters of 2026, and operating income and net income rose from the first to the second quarter. Management is delivering on expansion and profitability priorities, while higher commissions and personnel costs remain a factor; recent earnings have also been erratic, and a guidance cut would be a meaningful risk.
Over the next few quarters, the thesis depends on ITIC sustaining growth and improving profitability without expense increases eroding progress. Fed rate cuts could weigh on the financial sector, while stronger results and guidance from sector peers could support sector momentum.
For the next 1 to 3 years, ITIC’s long-term thesis rests on continued execution in expansion and profitability, with valuation providing a relatively favorable backdrop versus peers. The evidence is moderately confident, and the main risks are weaker guidance, expense pressure, and a less supportive rate environment. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Revenue is expected near $73.6 million in Q3 2025. |
| Intact |
| Revenue falls below $73.6 million in Q3 2025 |
Revenue: $86.503M FY2026-Q2; GAAP. Published target: >= $73.6 million. Target period ends 2025-09-30; this observation covers 2026-Q2. Aug 10, 202686,503,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain valuation below peer median PE of 15.34 | Its valuation is below peers, offering upside potential. | Intact | PE rises above 15.34 without earnings growth | P/E (TTM): 12.59x As of 2026-11-04; trailing twelve months. The target timing and basis require a separate assessment. Nov 4, 202612.5924 ratio · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.